Gefitinib monotherapy in advanced non-small cell lung cancer: Experience from a large, Western community, implementation study. Running title: Gefitinib for advanced non-small cell lung cancer (NSCLC)
نویسندگان
چکیده
Authors: R. van Puijenbroek, L. Bosquée, A-P. Meert, D. Schallier, J-C. Goeminne, G. Tits, P. Collard, K. Nackaerts, J-L Canon, F. Duplaquet, D. Galdermans, P. Germonpré, M-A. Azerad, G. Vandenhoven, J. De Greve, J. Vansteenkiste. Affiliations: Univ. Hospital, Catholic University, Leuven Citadelle Hospital, Liège Jules Bordet Institute, Brussels Univ. Hopsital VUB, Brussels St-Elisabeth Hospital, Namur St-Andries Hospital, Tielt Cliniques Universitaires St.-Luc, Brussels Notre Dame Hospital, Charleroi Univ. Hospital UCL, Yvoir Middelheim Hospital, Antwerp Univ. Hospital UIA, Antwerp Astra Zeneca Medical, Brussels
منابع مشابه
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and their long-term prognosis remains poor. Epidermal growth factor receptor (EGFR)-targeted therapies, such as gefitinib, have been subjected to comprehensive clinical development. Several phase II and III trials evaluated the clinical efficacy of gefitinib as monotherapy in pretreated patients with advanced NS...
متن کاملGefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
Epidermal growth factor receptor tyrosine kinase inhibitors represent a new treatment option for patients with advanced nonsmall cell lung cancer (NSCLC). This retrospective study examined to what extent previous clinical trial experience matches large-scale Western community implementation of this treatment. In the Belgian expanded access programme, the data from 513 patients with advanced or ...
متن کاملA review of the role of dopamine receptors and novel therapeutic strategies in non-small cell lung cancer (NSCLC)
Lung cancer is a very aggressive and most deadly cancer in both men and women. Lung cancer is divided into two types of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is divided into 3 subgroups: adenocarcinoma (AC), squamous cell carcinoma (SqCC) and large cell carcinoma (LCC). Dopamine is involved in controlling motions, cognition, emotions, memory and reward mech...
متن کاملGefitinib for advanced or metastatic non-small cell lung cancer.
Gefitinib is approved as monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have failed prior platinum-based treatment and docetaxel chemotherapy. Its efficacy when compared to standard treatment and best supportive care is unproven. Common drug-related adverse effects include gastrointestinal and skin disorders. Rare but serious d...
متن کاملTolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
PURPOSE We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). Here, we report on a post hoc subgroup analysis of that study assessing the demographics and disposition of the Korean patient subgroup, and comparing t...
متن کامل